591 related articles for article (PubMed ID: 32506725)
21. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
[TBL] [Abstract][Full Text] [Related]
22. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach.
van Tol S; Mögling R; Li W; Godeke GJ; Swart A; Bergmans B; Brandenburg A; Kremer K; Murk JL; van Beek J; Wintermans B; Reimerink J; Bosch BJ; Reusken C
Emerg Microbes Infect; 2020 Dec; 9(1):1965-1973. PubMed ID: 32819220
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
24. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
[TBL] [Abstract][Full Text] [Related]
25. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
İnandıklıoğlu N; Akkoc T
Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
[TBL] [Abstract][Full Text] [Related]
26. [Strategies for vaccine development of COVID-19].
Yang L; Tian D; Liu W
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
[TBL] [Abstract][Full Text] [Related]
27. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.
Wan Y; Shang J; Sun S; Tai W; Chen J; Geng Q; He L; Chen Y; Wu J; Shi Z; Zhou Y; Du L; Li F
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826992
[TBL] [Abstract][Full Text] [Related]
28. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
Burbelo PD; Riedo FX; Morishima C; Rawlings S; Smith D; Das S; Strich JR; Chertow DS; Davey RT; Cohen JI
J Infect Dis; 2020 Jun; 222(2):206-213. PubMed ID: 32427334
[TBL] [Abstract][Full Text] [Related]
30. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
Eroshenko N; Gill T; Keaveney MK; Church GM; Trevejo JM; Rajaniemi H
Nat Biotechnol; 2020 Jul; 38(7):789-791. PubMed ID: 32504046
[No Abstract] [Full Text] [Related]
31. Age-Related Differences in Immunological Responses to SARS-CoV-2.
Wong LSY; Loo EXL; Kang AYH; Lau HX; Tambyah PA; Tham EH
J Allergy Clin Immunol Pract; 2020; 8(10):3251-3258. PubMed ID: 32861856
[TBL] [Abstract][Full Text] [Related]
32. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
[TBL] [Abstract][Full Text] [Related]
33. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
Ou X; Liu Y; Lei X; Li P; Mi D; Ren L; Guo L; Guo R; Chen T; Hu J; Xiang Z; Mu Z; Chen X; Chen J; Hu K; Jin Q; Wang J; Qian Z
Nat Commun; 2020 Mar; 11(1):1620. PubMed ID: 32221306
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
[TBL] [Abstract][Full Text] [Related]
35. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
[TBL] [Abstract][Full Text] [Related]
36. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
37. The possible of immunotherapy for COVID-19: A systematic review.
AminJafari A; Ghasemi S
Int Immunopharmacol; 2020 Jun; 83():106455. PubMed ID: 32272396
[TBL] [Abstract][Full Text] [Related]
38. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway.
Jaume M; Yip MS; Cheung CY; Leung HL; Li PH; Kien F; Dutry I; Callendret B; Escriou N; Altmeyer R; Nal B; Daëron M; Bruzzone R; Peiris JS
J Virol; 2011 Oct; 85(20):10582-97. PubMed ID: 21775467
[TBL] [Abstract][Full Text] [Related]
39. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
40. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
